Last SFr.88.98 CHF
Change Today +0.10 / 0.11%
Volume 110.0K
NOVNEE On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
Xetra
New York
OTC US
Mexico
SIX Swiss Ex
Frankfurt
As of 11:15 AM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Mark C. Fishman M.D.

President of Institutes for Biomedical Research (NIBR) and Member of Executive Committee, Novartis AG
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 5 different industries.

63$7,540,279
As of Fiscal Year 2013

Background*

Dr. Mark C. Fishman, MD serves as Global Head of The Novartis Institute for BioMedical Research (NIBR) at Novartis AG and served as its President of BioMedical Research (NIBR) since 2002. Dr. Fishman serves as a Consultant in Medicine at the MGH. He serves as the President of BioMedical Research of Novartis Consumer Health, Inc. He has been the President of the Novartis Institutes for BioMedical Research (NIBR) of Novartis Institutes for BioMedical Research, Inc. since ...

Read Full Background

Corporate Headquarters*

Lichtstrasse 35
Basel, Basel-Stadt 4056

Switzerland

Phone: 41 61 324 11 11
Fax: --

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

MD 1976
Harvard Medical School
BA 1972
Yale College

Other Affiliations*

Annual Compensation*

Salary$990,000
Bonus$866,300
Total Annual Compensation$1,856,300

Stock Options*

Restricted Stock Awards$5,230,991
All Other Compensation$452,988
Total Number of Options327,594

Total Compensation*

Total Annual Cash Compensation$2,309,288
Total Short Term Compensation$1,856,300
Other Long Term Compensation$5,683,979
Total Calculated Compensation$7,540,279
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOVNEE:SW SFr.88.98 CHF +0.10

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
John C. Martin Ph.D.Chairman and Chief Executive Officer
Gilead Sciences Inc.
$1.6M
Alan George Lafley Chairman, Chief Executive Officer, President and Member of Proxy Committee
The Procter & Gamble Company
$6.4M
Ian C. Read Chairman, Chief Executive Officer and Chairman of Executive Committee
Pfizer Inc.
$1.8M
Kenneth C. Frazier Chairman and Chief Executive Officer
Merck & Co. Inc.
$1.5M
Serge Weinberg Chairman, Interim Chief Executive Officer, Chairman of Appointments & Governance Committee and Chairman of Strategy Committee
Sanofi
€700.0K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-2ND LINE, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.